JP2019506380A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019506380A5 JP2019506380A5 JP2018534683A JP2018534683A JP2019506380A5 JP 2019506380 A5 JP2019506380 A5 JP 2019506380A5 JP 2018534683 A JP2018534683 A JP 2018534683A JP 2018534683 A JP2018534683 A JP 2018534683A JP 2019506380 A5 JP2019506380 A5 JP 2019506380A5
- Authority
- JP
- Japan
- Prior art keywords
- alkanyl
- alkenyl
- cycloalkyl
- alkynyl
- heterocycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 O*(C(CSC1)=C1C(NCC(C(F)=CC(C1)c2ccccc2Cl)=C1F)=O)=O Chemical compound O*(C(CSC1)=C1C(NCC(C(F)=CC(C1)c2ccccc2Cl)=C1F)=O)=O 0.000 description 7
- PTVBNMXWRAJUSV-FQEVSTJZSA-N C=Cc(c(F)c(-c1cccc(OC(F)(F)F)c1)c(F)c1F)c1N[C@H](C(CCC1)=C1C(O)=O)O Chemical compound C=Cc(c(F)c(-c1cccc(OC(F)(F)F)c1)c(F)c1F)c1N[C@H](C(CCC1)=C1C(O)=O)O PTVBNMXWRAJUSV-FQEVSTJZSA-N 0.000 description 1
- AWQZPOVHLUISLX-UHFFFAOYSA-N CCOc1cccc(-c(cc2C)cc(F)c2NC(c2c[s]cc2C(O)=O)=O)c1 Chemical compound CCOc1cccc(-c(cc2C)cc(F)c2NC(c2c[s]cc2C(O)=O)=O)c1 AWQZPOVHLUISLX-UHFFFAOYSA-N 0.000 description 1
- BQZIYBRNHWXJMX-UHFFFAOYSA-N CN(C)c(cc1)ccc1-c(c(Cl)c1)ccc1NC(C(CCC1)=C1C(O)=O)=O Chemical compound CN(C)c(cc1)ccc1-c(c(Cl)c1)ccc1NC(C(CCC1)=C1C(O)=O)=O BQZIYBRNHWXJMX-UHFFFAOYSA-N 0.000 description 1
- OMPATGZMNFWVOH-UHFFFAOYSA-N COc1cc(-c(cc2F)cc(F)c2Nc(nccc2)c2C(O)=O)ccc1 Chemical compound COc1cc(-c(cc2F)cc(F)c2Nc(nccc2)c2C(O)=O)ccc1 OMPATGZMNFWVOH-UHFFFAOYSA-N 0.000 description 1
- GIUMGVUBDBDTDX-UHFFFAOYSA-N COc1cc(-c(cc2F)ccc2NC(c2c(C(O)=O)[s]cc2)=O)ccc1 Chemical compound COc1cc(-c(cc2F)ccc2NC(c2c(C(O)=O)[s]cc2)=O)ccc1 GIUMGVUBDBDTDX-UHFFFAOYSA-N 0.000 description 1
- YJRXMJJVGSJOSI-UHFFFAOYSA-N COc1cc(C(C=C2F)=CCC2NC(C(CCC2)=C2C(O)=O)=O)ccc1 Chemical compound COc1cc(C(C=C2F)=CCC2NC(C(CCC2)=C2C(O)=O)=O)ccc1 YJRXMJJVGSJOSI-UHFFFAOYSA-N 0.000 description 1
- AMVJOWMAEGAEQU-UHFFFAOYSA-N COc1cccc(-c(c(F)c(c(NC(c([o]cc2)c2C(O)=O)=O)c2F)F)c2F)c1 Chemical compound COc1cccc(-c(c(F)c(c(NC(c([o]cc2)c2C(O)=O)=O)c2F)F)c2F)c1 AMVJOWMAEGAEQU-UHFFFAOYSA-N 0.000 description 1
- PVWLYLAEVRTJCY-UHFFFAOYSA-N Cc1c(-c2cccc(OC(F)(F)F)c2)ncc(Nc(ccc(C2CC2)c2)c2C(O)=O)c1 Chemical compound Cc1c(-c2cccc(OC(F)(F)F)c2)ncc(Nc(ccc(C2CC2)c2)c2C(O)=O)c1 PVWLYLAEVRTJCY-UHFFFAOYSA-N 0.000 description 1
- ZJNYJBMNUPBYPR-UHFFFAOYSA-N Cc1cc(-c2cccc(OC(F)(F)F)c2)cc(F)c1NC(c1c[s]cc1C(O)=O)=O Chemical compound Cc1cc(-c2cccc(OC(F)(F)F)c2)cc(F)c1NC(c1c[s]cc1C(O)=O)=O ZJNYJBMNUPBYPR-UHFFFAOYSA-N 0.000 description 1
- MSDCJMPYXIKVBS-UHFFFAOYSA-N Nc1cccc(F)c1COc(ccc(NC(C1C(C(O)=O)=CCC1)=O)c1)c1F Chemical compound Nc1cccc(F)c1COc(ccc(NC(C1C(C(O)=O)=CCC1)=O)c1)c1F MSDCJMPYXIKVBS-UHFFFAOYSA-N 0.000 description 1
- YRNGPPFGPVIVQT-UHFFFAOYSA-N OC(C(CCC1)=C1C(Nc(cc1)cc(Cl)c1OCc(cccc1)c1F)=O)=O Chemical compound OC(C(CCC1)=C1C(Nc(cc1)cc(Cl)c1OCc(cccc1)c1F)=O)=O YRNGPPFGPVIVQT-UHFFFAOYSA-N 0.000 description 1
- SVANOUPJESQBHH-UHFFFAOYSA-N OC(C(CCC1)=C1C(Nc(cc1)cc(F)c1OCc(c(Cl)ccc1)c1F)=O)=O Chemical compound OC(C(CCC1)=C1C(Nc(cc1)cc(F)c1OCc(c(Cl)ccc1)c1F)=O)=O SVANOUPJESQBHH-UHFFFAOYSA-N 0.000 description 1
- QNIXUFHJBLJFFA-UHFFFAOYSA-N OC(C(CCC1)=C1C(Nc(cc1Cl)cc(Cl)c1OCc(c(F)ccc1)c1Cl)=O)=O Chemical compound OC(C(CCC1)=C1C(Nc(cc1Cl)cc(Cl)c1OCc(c(F)ccc1)c1Cl)=O)=O QNIXUFHJBLJFFA-UHFFFAOYSA-N 0.000 description 1
- GJRXGPXLDYJYHL-UHFFFAOYSA-N OC(CC1)C(C(Nc(c(F)c(c(-c2cccc(OC(F)(F)F)c2)c2F)F)c2F)=O)=C1C(O)=O Chemical compound OC(CC1)C(C(Nc(c(F)c(c(-c2cccc(OC(F)(F)F)c2)c2F)F)c2F)=O)=C1C(O)=O GJRXGPXLDYJYHL-UHFFFAOYSA-N 0.000 description 1
- CGNHUSCKOHDSMR-UHFFFAOYSA-N OC(c([s]cc1)c1C(Nc(c(F)cc(-c1cccc(OC(F)(F)F)c1)c1)c1F)=O)=O Chemical compound OC(c([s]cc1)c1C(Nc(c(F)cc(-c1cccc(OC(F)(F)F)c1)c1)c1F)=O)=O CGNHUSCKOHDSMR-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562273135P | 2015-12-30 | 2015-12-30 | |
| US62/273,135 | 2015-12-30 | ||
| PCT/US2016/069161 WO2017117372A1 (en) | 2015-12-30 | 2016-12-29 | Treatment of tumors incorporating mutant isocitrate dehydrogenase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019506380A JP2019506380A (ja) | 2019-03-07 |
| JP2019506380A5 true JP2019506380A5 (https=) | 2020-02-06 |
| JP6961879B2 JP6961879B2 (ja) | 2021-11-05 |
Family
ID=59225581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018534683A Expired - Fee Related JP6961879B2 (ja) | 2015-12-30 | 2016-12-29 | 変異体イソクエン酸デヒドロゲナーゼを包含する腫瘍の処置 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20190025313A1 (https=) |
| EP (1) | EP3397625A4 (https=) |
| JP (1) | JP6961879B2 (https=) |
| KR (1) | KR20180102105A (https=) |
| CN (1) | CN108699023A (https=) |
| AU (1) | AU2016380280B2 (https=) |
| CA (1) | CA3009826A1 (https=) |
| IL (1) | IL260326A (https=) |
| MX (1) | MX2018008169A (https=) |
| WO (1) | WO2017117372A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11730716B2 (en) | 2014-05-08 | 2023-08-22 | Kiora Pharmaceuticals Gmbh | Compounds for treating ophthalmic diseases and disorders |
| US20180369206A1 (en) | 2017-04-24 | 2018-12-27 | Aurigene Discovery Technologies Limited | Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors |
| HRP20211462T1 (hr) | 2017-04-24 | 2021-12-24 | Aurigene Discovery Technologies Limited | Postupci uporabe za trisupstituirane derivate benzotriazola kao inhibitora dihidroorotatne oksigenaze |
| TWI818954B (zh) | 2018-02-20 | 2023-10-21 | 法商施維雅藥廠 | 三取代之苯并三唑衍生物的使用方法 |
| WO2019170848A1 (en) | 2018-03-09 | 2019-09-12 | Panoptes Pharma Ges.M.B.H. | Ophthalmic formulation |
| JP7358373B2 (ja) * | 2018-03-16 | 2023-10-10 | イミュニック アクチェンゲゼルシャフト | 抗炎症薬、免疫調節薬及び抗増殖薬としての新規カルシウム塩多形 |
| EP3773579A4 (en) | 2018-03-26 | 2022-03-09 | Clear Creek Bio, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE |
| JP7126556B2 (ja) * | 2018-09-28 | 2022-08-26 | 富士フイルム株式会社 | シタラビンを含む抗腫瘍剤、シタラビンと併用される抗腫瘍効果増強剤、抗腫瘍用キット、およびシタラビンと併用される抗腫瘍剤 |
| WO2020113216A1 (en) * | 2018-11-30 | 2020-06-04 | Aptose Biosciences Inc. | Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations |
| JOP20210147A1 (ar) | 2018-12-21 | 2023-01-30 | Les Laboratoires Servier Sas | صور بلورية وملح من مركب عضوي وتركيبات صيدلانية منه |
| EP3750892A1 (en) | 2019-06-14 | 2020-12-16 | Yerevan State University | Novel 5-cyclopropyl-furo[3,4-c]pyridine-3,4(1h,5h)-dione 1,1' substituted derivatives and their uses |
| US11228361B2 (en) | 2019-10-25 | 2022-01-18 | Atlas Space Operations, Inc. | System and method for configuring a communications device for space-terrestrial communications |
| AU2020412805A1 (en) * | 2019-12-26 | 2022-07-14 | Hendrix College | Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-CD38 therapeutic agent |
| WO2021189018A1 (en) | 2020-03-20 | 2021-09-23 | Clear Creek Bio, Inc. | Methods of treating viral infections using inhibitors of nucleotide synthesis pathways |
| WO2022167402A1 (en) * | 2021-02-02 | 2022-08-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of therapy comprising administering a therapeutically effective combination comprising a dhodh inhibitor and an idh inhibitor |
| AU2022222470A1 (en) | 2021-02-19 | 2023-09-21 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| EP4294806A1 (en) | 2021-02-19 | 2023-12-27 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| CA3208361A1 (en) | 2021-02-19 | 2022-08-25 | Anjali Pandey | Tyk2 inhibitors and uses thereof |
| EP4319766A4 (en) * | 2021-04-08 | 2025-05-28 | Memorial Sloan Kettering Cancer Center | NADK2 INHIBITION IN CANCER AND FIBROTIC DISEASES |
| WO2023168176A1 (en) * | 2022-03-01 | 2023-09-07 | Kiora Pharmaceuticals Gmbh | Salts of a dihydroorotate dehydrogenase (dhod) inhibitor |
| WO2023172818A1 (en) * | 2022-03-09 | 2023-09-14 | Kiora Pharmaceuticals Gmbh | Polymorphs of a dihydroorotate dehydrogenase (dhod) inhibitor |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003006424A1 (en) * | 2001-07-10 | 2003-01-23 | 4Sc Ag | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| US9316632B2 (en) * | 2009-03-17 | 2016-04-19 | Marshall University Research Corporation | Methods of screening chemotherapeutic agents and treating cancer |
| ES2642109T3 (es) * | 2009-12-09 | 2017-11-15 | Agios Pharmaceuticals, Inc. | Compuestos terapéuticamente activos para su uso en el tratamiento de cáncer caracterizados por tener una mutación de IDH |
| WO2013049112A1 (en) * | 2011-09-27 | 2013-04-04 | Emory University | Detection of biomarkers using magnetic resonance |
| US11730716B2 (en) * | 2014-05-08 | 2023-08-22 | Kiora Pharmaceuticals Gmbh | Compounds for treating ophthalmic diseases and disorders |
| US11096934B2 (en) * | 2015-09-01 | 2021-08-24 | The Broad Institute, Inc. | Compounds and methods useful for treating or preventing hematological cancers |
-
2016
- 2016-12-29 JP JP2018534683A patent/JP6961879B2/ja not_active Expired - Fee Related
- 2016-12-29 KR KR1020187021446A patent/KR20180102105A/ko not_active Withdrawn
- 2016-12-29 MX MX2018008169A patent/MX2018008169A/es unknown
- 2016-12-29 US US16/066,984 patent/US20190025313A1/en not_active Abandoned
- 2016-12-29 CA CA3009826A patent/CA3009826A1/en not_active Abandoned
- 2016-12-29 WO PCT/US2016/069161 patent/WO2017117372A1/en not_active Ceased
- 2016-12-29 CN CN201680077339.9A patent/CN108699023A/zh active Pending
- 2016-12-29 AU AU2016380280A patent/AU2016380280B2/en not_active Expired - Fee Related
- 2016-12-29 EP EP16882651.9A patent/EP3397625A4/en not_active Withdrawn
-
2018
- 2018-06-28 IL IL260326A patent/IL260326A/en unknown
-
2020
- 2020-09-01 US US17/009,126 patent/US20210088520A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019506380A5 (https=) | ||
| AU2020302352B2 (en) | Quinazolin-4-one derivatives useful for the treatment of BRAF-associated diseases and disorders | |
| JP6575950B2 (ja) | Ｂｒｕｔｏｎ型チロシンキナーゼ（Ｂｔｋ）阻害剤に対する耐性を伴う変異 | |
| Li et al. | Development of anaplastic lymphoma kinase (ALK) small‐molecule inhibitors for cancer therapy | |
| JP2022535880A5 (https=) | ||
| US10441587B2 (en) | Treatment of lung cancer with inhibitors of glutaminase | |
| JP2023512039A (ja) | 化合物及びその使用 | |
| US20230233565A1 (en) | A treatment approach involving kif18a inhibition for chromosomally unstable tumors | |
| JP2020503009A5 (https=) | ||
| RS55545B1 (sr) | Postupci lečenja korišćenjem selektivnih bcl-2 inhibitora | |
| Takahara et al. | Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer | |
| JP2017502967A5 (https=) | ||
| ES2429041T3 (es) | Combinación de un agente quimioterapéutico y un antagonista de un producto génico para tratar tumores | |
| UA126478C2 (uk) | Інгібітори fgfr2 для лікування холангіокарциноми | |
| JP2017527287A (ja) | タンパク質キナーゼ阻害剤に対する感受性予測用バイオマーカー及びその用途 | |
| Rohrberg et al. | Detecting and targeting NTRK fusions in cancer in the era of tumor agnostic oncology | |
| Tarazona et al. | Personalised treatment in gastric cancer: myth or reality? | |
| Iurlo et al. | Management of myelofibrosis: from diagnosis to new target therapies | |
| Asai et al. | Comparison of the effects of baricitinib and tocilizumab on disease activity in patients with rheumatoid arthritis: a propensity score matching analysis | |
| JP2023534991A (ja) | 変異型ｉｄｈ１阻害剤、デオキシアデノシン類似体、及び白金剤を用いた併用療法 | |
| JP2021500331A (ja) | Ｔｄｐ−４３関連疾患の予防及び治療 | |
| WO2020219926A1 (en) | Treatment of cancer with cdk inhibitors | |
| WO2007140924A1 (en) | Use of vascular endothelial growth factor receptor inhibitors for the treatment of cancer | |
| Malla et al. | Emerging therapeutic advancements in pancreatic cancer: a contemporary review | |
| Zhou et al. | Human MutT homologue 1 mRNA overexpression correlates to poor response of multiple myeloma |